Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis and Gates Foundation Ink Sickle Cell Gene Therapy Pact

Seeking Low-Cost Practical Option For Sub-Saharan Africa

Executive Summary

The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.

You may also be interested in...



Big Pharmas Back $300m Neglected Disease Fund

Adjuvant Capital believes its fund will ultimately lead to greater access to medical advances in low-income countries while making a healthy return for its high-profile investors.

Bluebird Sickle Cell Gene Therapy Hangs In Balance

The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.” 

Sickle Cell And Beta-Thalassemia Bend To Gene Manipulation By CRISPR/Vertex And Bluebird

Data for new genetic methods to tackle severe hemoglobinopathies presented at the EHA meeting bring more confidence for bluebird’s gene therapy LentiGlobin and early suggestions of a functional cure with CRISPR gene editing with CRISPR Therapeutics/Vertex’s CTX001.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143837

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel